SGHT · Sight Sciences, Inc. · Webcasts, Transcripts & Audio
$10.83
-0.16 (-1.46%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$601.92M
Shares
55.58M
Volume · Nov 13
223.74K
Avg daily vol (3M)
314.3K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Sight Sciences, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Sight Sciences, Inc. (SGHT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Sight Sciences, Inc. (SGHT) Q3 2026 Earnings Call Transcript
Revenue
$24.92M
▲ 25.2% YoY Diluted EPS
$-0.12
Gross margin
85.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Sight Sciences, Inc. (SGHT) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
Confident tone
Interventional Glaucoma / Omni platform
Payer coverage and market access expansion
Path to profitability / cash flow discipline
Revenue
$23.39M
▲ 19.5% YoY Diluted EPS
$-0.08
Gross margin
91.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-13
Sight Sciences, Inc. (SGHT) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Confident tone
Interventional Glaucoma (Omni) Growth
Market Access Expansion (MACs and Commercial Payers)
Intersection of Intervention (Cross-Selling Synergies)
Revenue
$19.70M
▲ 12.5% YoY Diluted EPS
$-0.24
Gross margin
86.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Positive tone
2026 financial guidance and growth outlook
Interventional Dry Eye / TearCare commercialization
MAC reimbursement expansion
Revenue
$20.39M*
▲ 6.9% YoY Gross margin
87.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Confident tone
TearCare reimbursement and MAC coverage
Surgical Glaucoma / OMNI growth
2025 guidance raise
Revenue
$19.91M
▼ 1.2% YoY Diluted EPS
$-0.16
Gross margin
86.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript
Revenue
$19.56M
▼ 8.5% YoY Diluted EPS
$-0.23
Gross margin
84.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript
Positive tone
Omni surgical glaucoma performance
TearCare reimbursement progress
Dry eye segment growth
Revenue
$17.51M
▼ 9.1% YoY Diluted EPS
$-0.28
Gross margin
86.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-14
Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Call Transcript
Cautious tone
Surgical Glaucoma (OMNI) Performance and Strategy
TearCare Reimbursement and Dry Eye Progress
MIGS Market Headwinds and LCD Restrictions
Revenue
$19.07M*
▲ 1.7% YoY Gross margin
86.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript
Cautious tone
Surgical Glaucoma / MIGS Market Recovery
TearCare / Dry Eye Franchise and Payer Access
OMNI Product and Clinical Profile
Revenue
$20.16M
▲ 0.7% YoY Diluted EPS
$-0.22
Gross margin
83.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript
Confident tone
Dry Eye / TearCare Commercialization and Coverage
SAHARA Clinical Data and Health Economics
TearCare Price Increase and Adoption
Revenue
$21.37M
▼ 9% YoY Diluted EPS
$-0.25
Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript
Positive tone
Surgical Glaucoma growth and recovery
Dry Eye / TearCare business
Sales force and commercial scaling
Revenue
$19.27M
▲ 2.3% YoY Diluted EPS
$-0.33
Gross margin
85.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript
Positive tone
Surgical Glaucoma / OMNI Performance
LCD Reimbursement Uncertainty
2024 Guidance & Growth Outlook
Revenue
$18.75M*
▼ 8.7% YoY Gross margin
85.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript
Revenue
$20.01M
▲ 7.1% YoY Diluted EPS
$-0.27
Gross margin
86.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Sight Sciences, Inc. (SGHT) Q2 2023 Earnings Call Transcript
Revenue
$23.47M
▲ 36.2% YoY Diluted EPS
$-0.30
Gross margin
85.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Sight Sciences, Inc. (SGHT) Q1 2023 Earnings Call Transcript
Revenue
$18.82M
▲ 26.5% YoY Diluted EPS
$-0.35
Gross margin
83.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Sight Sciences, Inc. (SGHT) Q4 2022 Earnings Call Transcript
Revenue
$20.54M*
▲ 39.9% YoY Gross margin
82.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Sight Sciences, Inc. (SGHT) Q3 2022 Earnings Call Transcript
Revenue
$18.68M
▲ 42.6% YoY Diluted EPS
$-0.46
Gross margin
84.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Sight Sciences, Inc. (SGHT) Q2 2022 Earnings Call Transcript
Revenue
$17.23M
▲ 37.4% YoY Diluted EPS
$-0.50
Gross margin
84.1%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Sight Sciences, Inc. (SGHT) Q1 2022 Earnings Call Transcript
Revenue
$14.88M
▲ 72.3% YoY Diluted EPS
$-0.49
Gross margin
79.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-24
Sight Sciences, Inc. (SGHT) Q4 2021 Earnings Call Transcript
Revenue
$14.69M*
Gross margin
86.8%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Sight Sciences, Inc. (SGHT) Q3 2021 Earnings Call Transcript
Revenue
$13.10M
▲ 51.4% YoY Diluted EPS
$-0.43
Gross margin
84.3%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Sight Sciences, Inc. (SGHT) Q2 2021 Earnings Call Transcript
Revenue
$12.54M
▲ 257.9% YoY Gross margin
81.6%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–24 of 24 webcasts
Key facts
CIK
1531177
CUSIP
82657M105
13F (30d)
93 filings
79 filers
Visit website
Investor relations